DOI:
10.1055/s-00000002
Aktuelle Dermatologie
LinksClose Window
References
Davies MA, Saiag P, Robert C. et al.
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.
The Lancet Oncology 2017;
18: 863-873
DOI: 10.1016/S1470-2045(17)30429-1.
We do not assume any responsibility for the contents of the web pages of other providers.